Efficacy And Safety Of A Biodegradable Polymer-coated Sirolimus-eluting Stent Compares With Permanent Stent In Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Background:Several clinical trials have shown that rapamycin-eluting stents significantly reduce the risk of restenosisafter percutaneous coronary intervention(PCI). Drug-eluting stents (DES)were primarily conceived to reduce in-stent neointimal formation, The development of DES has been pioneered through acombination of the increased understanding of the biology of restenosis o DES Systems With Bioabsorbable (Biodegradable) Polymers-EXCELstent (JW Medical Systems, Weihai, China) the concept of a polymer that carries and controls the drug release during an proper period of time and after that erodes and vanishes from the vascular surface seems to be very attractive. It presented in this section utilize poly-1-lactic acid (PLLA) which are progres-sively erode by shortened as ester bonds and ultimately will degrade into. Water and carbon dioxide after three or six year.Aim:To evaluate the efficacy and safety of a novel non-symmetrical, biodegradable polymer-coated sirolimus-eluting stent (NSBP-SES) in patients with ST-segment elevation acute myocardial infarction (STEMI).Data and methods:The consecutive patients with AMI, admitted in Zhongshan Hospital between2007.1and2009.12are registered, and the follow-up is made in March,2011.。171patients who received NSBP-SES versus,249patients who received a traditional symmetrical, durable polymer-coated sirolimus-eluting stent (SDP-SES) during primary percutaneous coronary intervention for AMI. The information recorded includes cardiac mortality, recurrent myocardial infarction, revascularization, reischemia, cardiac function,main cardiac events (identified as at least one of the cardiac mortality, recurrent myocardial infarction, revascularization, reischemia,) The primary endpoint was target lesion failure (TLF) at12months. The data is analyzed with SPSS, p<0.05means statistically difference.ResultsA total of420patients are enrolled,171patients who received NSBP-SES versus249patients who received a traditional symmetrical, durable polymer-coated sirolimus-eluting stent (SDP-SES) during primary percutaneous coronary intervention for AMI. The follow-up is obtained in403patients, and the mean follow-up time is12months. There was no significant difference in the rate of12-month TLF (5.8%versus5.6%; P=1.0), cardiac death (4.1%versus5.2%; P=0.65), non-fatal re-infarction (1.2%versus0.4%; P=0.57), target lesion revascularization (1.8%versus0.4%; P=0.31), or stent thrombosis (0.6%versus1.6%; P=0.65) between the two groups. The use of NSBP-SES in real-world patients with STEMI appears to be efficacy and safe when compared with SDP-SES. Further investigation is warranted to validate the long-term efficacy and safety.Conclusions The use of NSBP-SES in real-world patients with STEMI appears to be efficacy and safe when compared with SDP-SES. Further investigation is warranted to validate the long-term efficacy and safety.